Use of panitumumab (Pmab) and cetuximab (Cmab), anti-endothelial growth factor receptor (EGFR) antibodies, has resulted in earlier tumor shrinkage for K-ras wild type metastatic colorectal cancer[4]. This evidence concerns the gene EGFR and metastatic colorectal cancer.